【BIOSIS 7193 交流专区】 生物科学

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 31 Mar 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		31 Mar 2015	31 Mar 2014	31 Mar 2015	31 Mar 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	3,714	3,294	13,047	8,481
2	Profit/(loss) before tax	-4,190	-9,815	-3,970	-39,961
3	Profit/(loss) for the period	-4,001	-9,638	-3,794	-39,061
4	Profit/(loss) attributable to ordinary equity holders of the parent	-3,116	-8,313	-2,658	-40,798
5	Basic earnings/(loss) per share (Subunit)	-2.97	-7.92	-2.53	-38.86
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	-0.2700		-0.2400

icy97

交易所否决重组计划　保优生10日起暂停交易

财经  2015年06月02日
（吉隆坡2日讯）保优生（BIOSIS，7193，主板消费股）的重组计划被大马交易所正式否决，並遭勒令於6月10日（週三）起暂停交易。

该公司早於2013年，便因股东基金低於已发行及缴足资本的50%，而被列为PN17公司。而保优生通过出租製造器材及减低营运成本，业绩在去年末季有所改善，亏损降至831万令吉，2013財政年末季亏损为1225万令吉。

2015財政年（3月31日结账）的全年净亏损，则从2014財政年的4079万令吉，收窄至266万令吉。虽如此，其重组计划仍无法通过交易所批准。若保优生无法在7月2日（週四）前提出上诉，该公司將在7月7日（週二）正式除牌。【东方网财经】

BIOSIS - Suspension and De-listing pursuant to Practice Note 17

BIOSIS GROUP BERHAD

Bursa Malaysia Securities Berhad has rejected BIOSIS' proposed regularisation plan.

In the circumstances and pursuant to paragraph 8.04(5) of the Main LR:-

(a) the trading in the securities of BIOSIS will be suspended with effect from 10 June 2015; and

(b) the securities of BIOSIS will be de-listed on 7 July 2015 unless an appeal against the rejection of the regularisation plan and de-listing is submitted to Bursa Securities on or before 2 July 2015 (the “Appeal Timeframe”).  Any appeal submitted after the Appeal Timeframe will not be considered by Bursa Securities.

In the event BIOSIS submits an appeal to Bursa Securities within the Appeal Timeframe, the removal of the securities of BIOSIS from the Official List of Bursa Securities on 7 July 2015 shall be deferred pending the decision on the company’s appeal.

With respect to the securities of BIOSIS which are currently deposited with Bursa Malaysia Depository Sdn Bhd ("Bursa Depository"), the securities may remain deposited with Bursa Depository notwithstanding the de-listing of the securities from the Official List of Bursa Securities.  It is not mandatory for the securities of a company which has been de-listed to be withdrawn from Bursa Depository.

Alternatively, shareholders of BIOSIS who intend to hold their securities in the form of   physical certificates, can  withdraw these securities from their Central Depository System (CDS) accounts maintained with Bursa Depository at anytime after the securities of the company have been de-listed from the Official List of Bursa Securities.  This can be effected by the shareholders submitting an application form for withdrawal in accordance with the procedures prescribed by Bursa Depository. These shareholders can contact any Participating Organisation of Bursa Securities and/or Bursa Securities’ General Line at 03-2034 7000 for further information on the withdrawal procedures.

Upon the de-listing of BIOSIS, the company will continue to exist but as an unlisted entity.  BIOSIS is still able to continue its operations and business and proceed with its corporate restructuring and its shareholders can still be rewarded by the company’s performance.  However, the shareholders will be holding shares which are no longer quoted and traded on Bursa Securities.

APULA

保優生申請延後除牌‧股價一度重挫86.36%
2015-06-03 17:08
http://biz.sinchew.com.my/node/116684

（吉隆坡3日訊）保優生（BIOSIS，7193，主板消費品組）重組計劃遭大馬股票交易所駁回，股票將從6月10日起暫停交易，並在7月7日除牌，受這消息打擊，該公司股價一度重挫86.36%。

保優生董事部在6月2日向交易所提出上訴，因此7月7日除牌日期將延後，以等待上訴結果。同時該公司表示，即使除牌，該公司還是會以非上市方式經營業務。

保優生：交易所忽視重組計劃幾項重點

該公司認為交易所拒絕該公司的重組計劃，是沒有考慮重組計劃中的幾方面，包括增加主要管理人員，重委董事和公司已經有營運盈利。

計劃中加了新元素，除了加速扭轉公司表現，也著重於交易所要求的財務指標表現。

保優生也覺得交易所忽略了公司營運盈利。該公司在2015年3月31日單季和全年都已經錄得營運盈利。“期間虧損主要是虧損撥備所致，一旦完成重組，有關扭轉續劣勢。

交易所週二發文告表示，除非保優生在7月2日前對重組計劃遭駁回一事提出上訴，否則其股票將從7月7日起除牌下市。

保優生是基於股東基金不足繳足資本50%，於2013年6月陷入PN17公司行列，後建議展開削資、併股、私下配售，以及1配1送1比例發售和配送附加股和憑單等系列重組計劃，以脫離PN17公司行列，但遭交易所駁回。

除牌消息一出，該公司股價今日蒙受重挫，一開始就大跌4仙至7仙，過後股價江河直瀉，一度寫下1.5仙全日最低，大跌9.5仙或86.36%。

今日收市，該公司股價報2仙，下跌9仙或81.81%，全日成交量389萬2千800股。

受詢分析員說，交易所駁回保優生重組計劃，對該公司是當頭棒喝。據知，該公司從2012年就開始計劃企業重組計劃。

保優生2004年在馬股上市，核心業務包括生產個人衛生產品及醫療產品、行銷及零售。該公司在2013年6月27日成為PN17陷困公司。

該公司在截至2014年3月31日止的累積虧損為7千813萬令吉。（星洲日報／財經）

Type	Announcement
Subject	PRACTICE NOTE 17 / GUIDANCE NOTE 3 REGULARISATION PLAN
Description	BIOSIS GROUP BERHAD (BIOSIS OR COMPANY) PROPOSED REGULARISATION PLAN PURSUANT TO PARAGRAPH 8.04 AND PRACTICE NOTE NO. 17 ("PN17") OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") ("MAIN LR")
We refer to the announcements dated 26 June 2013, 6 June 2014, 20 September 2014, 30 September 2014, 26 November 2014, 16 December 2014 and 30 January 2015 and the monthly status announcements relating to the Company’s condition pursuant to PN17 of the Main Market Listing Requirements of Bursa Malaysia Securities Berhad, and the application dated 30 September 2014 in relation to the above (“the Application”). On behalf of BIOSIS, SJ Securities Sdn Bhd ("SJ Securities") wishes to inform Bursa Securities has vide its letter dated 2 June 2015 stated that after due consideration of all facts and circumstances of the matter, it has decided to reject the Company’s Proposed Regularisation Plan (as defined as in the Application) as the Company and its Principal Adviser has not demonstrated to the satisfaction of Bursa Securities on the ability of the Proposed Regularisation Plan to comply with Paragraph 5.4 of PN17 of the Main LR which specifies that the regularisation plan must be sufficiently comprehensive and capable of resolving all problems, financial or otherwise that had caused the Company to trigger the Prescribed Criteria (as defined in the Main LR), based on the following grounds:- (i)  BIOSIS continues to rely on its existing business to turnaround the Company’s financial condition as part of the Proposed Regularisation Plan and it is noted that BIOSIS has registered continuing losses on a consolidated basis for the past six (6) financial years. Since being classified as a PN17 company on 26 June 2013, the initiatives that were undertaken by the Company to streamline operations and increase production has not resulted in a turnaround on the financial performance of the Company as the Company continues to register gross loss and loss from operations for the financial year ended 31 March 2014 as well as for the two financial periods ended 30 September 2014 and 31 December 2014. There are concerns on the ability of the Company to sustain and grow the revenue and profitability form its existing business given the following:    (a) the Company has minimum contracts on hand to generate significant revenue and there are uncertainties as to whether the Company can successfully execute its new business         model to generate significant revenue given that the Company is still in negotiations for tenders for specific pharmaceutical products and in negotiations with prospective                     partners with whom it intends to form business collaboration; and    (b) the Company has products where research and development has been completed and registration approved since 2004 but have not been significantly commercialise to  address         the financial condition of the BIOSIS Group. As such, the Company and its Principal Adviser has failed to satisfactorily address Bursa Securities concerns on the ability of the Company to sustain and grow the revenue and profitability from the existing core business of the BIOSIS Group. (ii) The Company and its Principal Adviser has failed to satisfactorily address Bursa Securities concerns on the ability of the Company to record a net profit for 2 consecutive quarterly results immediately after the completion of the implementation of the plan given amongst others, issues highlighted in (i) above; and (iii) The Company’s accumulated losses stood at approximately RM78.13 million as at 31 March 2014 which will be reduced to approximately RM18.42 based on BIOSIS’s Proposed Regularisation Plan. Given the issued raised above, there are concerns on the ability of the BIOSIS Group to fully eliminated the accumulated losses under the Proposed Regularisation Plan in the near future. The securities of the Company shall be removed from the Official List of Bursa Securities on such date as may be specified by Bursa Securities, subject to the Company’s right to appeal against the rejection of the regularisation plan pursuant to Paragraph 8.04(4) of the Main LR. The Company is of the view that in arriving at the above decision, certain aspects of the Company’s turnaround plan may not have considered , in particular, the recent changes in the Company which include the following: A recent change in regime within the BIOSIS Group through the addition of new key management team personnel and, the new appointments and redesignation of directors; The new regime is refining and supplementing the Proposed Regularisation Plan in order to accelerate the turnaround efforts to better address the concerns of Bursa Securities; and The BIOSIS Group had turned in profits from operations in its latest unaudited quarterly result for the quarter ended 31 March 2015 and also for the financial year ended 31 March 2015, and the losses and/or lack of apparent profitability for the period up to 31 March 2015 are mainly due to impairments and provisions made, and accrued interest that would be reversed upon completion of the implementation of the Proposed Regularisation Plan. The Board will deliberate on the above matter and will make the relevant announcements in due course. This announcement is dated 3 June 2015.

icy97

Date of change	01 Jun 2015
Name	Encik JAMALUDIN BIN ELIS
Age	50
Nationality	Malaysia
Designation	Director
Directorate	Executive
Type of change	Appointment
Qualifications	1. Executive Certificate for MBA Holders, Harvard Business School (HBS), Harvard University (2008)2. MBA, Southern Cross University, Australia (2005)3. BSc. Engineering (Mechanical), Brighton Polytechnic (1988)
Working experience and occupation	1. Commercial Director of Pharmaniaga Berhad (2011-2014)2. Senior General Manager, Business Development/ Corporate Strategy of Pharmaniaga Berhad (2010-2011)        3. Senior General Manager Manufacturing Division of Pharmaniaga Manufacturing Berhad (2007-2009)4. General Manager (Plant) Safire Pharmaceuticals of Safire Pharmaceuticals Sdn Bhd (2005-2007)5. Factory Manager of Meditop Corporation Sdn Bhd (2002-2005)6. Business Development Manager of Inspired Technologies Sdn Bhd (1999-2001)7. Operations Director/Executive Director of Popular Profile Sdn Bhd (1994-1998)8. Manufacturing Engineer of Delta Switchgear Sdn Bhd (1988-1994)

icy97

生物科学承认 改革重点没呈马交所

财经新闻 财经  2015-06-06 11:42
（吉隆坡5日讯）PN17公司生物科学（BIOSIS，7193，主板消费产品股）承认，并未将重组计划的某些重要方案，提呈予马交所。

根据文告，生物科学在马交所拒绝重组计划之前，并没呈上某些改革方案，包括委任和重新调任董事、额外增添主要管理层及亏损收窄的上财年业绩。

因此，生物科学正商议采取进一步行动，包括向马交所提出上诉及将没有呈上改革方案的讯息，知会马交所。

早前，马交所拒绝生物科学重组计划，公司将在10日暂停交易，除非公司在7月2日或之前，向马交所提出上诉，否则将在7月7日被除牌。

公司不满重组计划被拒，指马交所没把改革方案中的某些计划，纳入决策考量，也忽略了营运净利。

闭市时，生物科学报4仙，全日跌0.5仙，总成交量为99万7300股。【南洋网财经】

Type	Announcement
Subject	PRACTICE NOTE 17 / GUIDANCE NOTE 3 REGULARISATION PLAN
Description	BIOSIS GROUP BERHAD ("BIOSIS" OR "COMPANY") PROPOSED REGULARISATION PLAN PURSUANT TO PARAGRAPH 8.04 AND PRACTICE NOTE NO. 17 ("PN17") OF THE MAIN MARKET LISTING REQUIREMENTS OF BURSA MALAYSIA SECURITIES BERHAD ("BURSA SECURITIES") ("MAIN LR")
We refer to the announcement dated 3 June 2015 relating to Bursa Securities’ decision on the Company’s application dated 30 September 2014 in relation to the above (“the Application”). On behalf of BIOSIS, SJ Securities Sdn Bhd ("SJ Securities") wishes to clarify on the following: Full details of the recent change in regime within the BIOSIS Group as mentioned in the last paragraph of the announcement on 3 June 2015 have not been submitted or communicated to Bursa Securities before its decision on 2 June 2015; Full details of the efforts of the new regime in refining and supplementing the Proposed Regularisation Plan as mentioned in the last paragraph of the announcement on 3 June 2015 have not been submitted or communicated to Bursa Securities before its decision on 2 June 2015; and Full details of the Company’s analysis of its performance for the quarter ended 31 March 2015 and the year ended 31 March 2015 as mentioned in the last paragraph of the announcement on 3 June 2015 have not been submitted or communicated to Bursa Securities before its decision on 2 June 2015. The Board is still deliberating on the next course of action to be taken, including appealing against the said decision of Bursa Securities and the communication of the above to Bursa Securities, and will make the necessary announcement in due course. 0This announcement is dated 4 June 2015.

icy97

生物科学联手YBU 控股 霹建医疗器材翻新园

财经新闻 财经  2015-06-20 11:42
（吉隆坡19日讯）生物科学（BIOSIS，7193，主板消费产品股）与YBU控股私人有限公司签署了解备忘录，在霹雳联营发展东南亚首个医疗器材翻新和创新园区。

该园区位于霹雳州拉律马登县的彭卡兰阿儿（Pengkalan Aor），占地45.16英亩。

YBU控股将负责向霹雳州土地局买地，备忘录期限为12个月。

生物科学向马交所报备，其独资子公司生物科学发展有限公司（BSDB）和YBU控股，将会根据双方同意的持股比例，并结合双方的专业，共同拥有及经营该园区。

另外，Chulia医疗方案私人有限公司，将成为该项目的技术伙伴，同时也被允许拥有股权。

YBU控股是霹雳能力建设基金会（Yayasan Bina Upaya Darul Ridzuan）的投资臂膀。

文告表示，这项联营计划将会改善生物科技2016财年的业绩。【南洋网财经】

Type	Announcement
Subject	MEMORANDUM OF UNDERSTANDING
Description	BIOSIS GROUP BERHAD (BIOSIS" OR "THE COMPANY")Memorandum of Understanding (MOU) with YBU Holdings Sdn Bhd
The Board of Directors of Biosis Group Berhad (“BIOSIS”) is pleased to announce that Biosis Development Sdn Bhd, a wholly-owned subsidiary of BIOSIS has on 17 June 2015 entered into a Memorandum of Understanding ("MOU") with YBU Holdings Sdn Bhd (923233-U) (“YBUH") for the establishment of joint venture to develop and operate the first Medical Device Refurbishment & Innovation Park in Southeast Asia. Please refer to the attachment for further details on the MOU. This announcement is dated 18 June 2015.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/4776981

Attachments MoU with YBUH.pdf

icy97

Type	Reply to Query
Reply to Bursa Malaysia's Query Letter - Reference ID	IQL-19062015-00001
Subject	MOU with YBU Holdings Sdn Bhd ("YBUH")
Description	BIOSIS GROUP BERHAD (BIOSIS" OR "THE COMPANY")Memorandum of Understanding (MOU) with YBU Holdings Sdn Bhd
Query Letter Contents	We refer to your Company’s announcement dated 18 June 2015, in respect of the aforesaid matter. In this connection, kindly furnish Bursa Securities with the following additional information for public release:- 1.      Detail information of the proposed Health & Medical Technology Innovation Park (“Park”), including but not limited to, the objective of setting up the Park, the authorities/government agency that initiate the setting of the Park, the types of products to be produced and/or services to be rendered as well as the target markets for the products and/or services; 2.      Detail clarification as to how the Group would benefit, financially and operationally, from participating in the proposed joint venture to develop and operate the Park; 3.      The estimated financial commitment for the Group to finance the development of the Park and the source of funds; 4.      The prospects of the project; 5.      Details of the directors and major shareholders of YBUH together with their respective shareholdings; 6.      Background information of Chulia Medical Solutions Sdn Bhd, including but not limited to, its principal activities, identity of the directors and major shareholders, as well as its specific roles as the technical partner for the project; 7.      Details and elaboration on the 4 components of the project to be co-established by Biosis Development Sdn Bhd (“BDSB”); 8.      Further clarification of the experience and expertise of BDSB in undertaking the project in health and medical products taking into consideration that BDSB is principally a property development company; and 9.      Quantification of percentage shareholdings of Encik Hamzarul Hazmir bin Hamdan in BIOSIS as at the latest practicable date.
Further to our general announcement made on 18 June 2015, we are pleased to provide further information in respect of the MOU. Please refer to the attachment for further details. This announcement is dated 23 June 2015.

http://www.bursamalaysia.com/market/listed-companies/company-announcements/4780501

Attachments Bursa reply on MoU with YBUH 220615 (amended).pdf

icy97

SUMMARY OF KEY FINANCIAL INFORMATION 30 Jun 2015

		INDIVIDUAL PERIOD		CUMULATIVE PERIOD
		CURRENT YEAR QUARTER	PRECEDING YEAR CORRESPONDING QUARTER	CURRENT YEAR TO DATE	PRECEDING YEAR CORRESPONDING PERIOD
		30 Jun 2015	30 Jun 2014	30 Jun 2015	30 Jun 2014
		$$'000	$$'000	$$'000	$$'000

1	Revenue	4,484	4,046	4,484	4,046
2	Profit/(loss) before tax	269	247	269	247
3	Profit/(loss) for the period	269	234	269	234
4	Profit/(loss) attributable to ordinary equity holders of the parent	335	354	335	354
5	Basic earnings/(loss) per share (Subunit)	0.32	0.34	0.32	0.34
6	Proposed/Declared dividend per share (Subunit)	0.00	0.00	0.00	0.00
		AS AT END OF CURRENT QUARTER		AS AT PRECEDING FINANCIAL YEAR END
7	Net assets per share attributable to ordinary equity holders of the parent ($$)	-0.2700		-0.2800

icy97

De-listing of Biosis Group Berhad

BIOSIS GROUP BERHAD

Bursa Malaysia Securities Berhad (Bursa Securities) had dismissed Biosis Group Berhad’s appeal against rejection of the company's proposed regularisation plan and de-listing of the company's securities pursuant to paragraph 8.04 of the Bursa Securities Main Market Listing Requirements.

In the circumstances, the securities of the company will be removed from the Official List of Bursa Securities on Monday, 23 November 2015.

Effect of De-listing from the Official List of Bursa Securities

With respect to the securities of the company which are currently deposited with Bursa Malaysia Depository Sdn Bhd (Bursa Depository), the securities may remain deposited with Bursa Depository notwithstanding the de-listing of the securities from the Official List of Bursa Securities. It is not mandatory for the securities of a company which has been de-listed to be withdrawn from Bursa Depository.

Alternatively, shareholders of the company who intend to hold their securities in the form of physical certificates can withdraw these securities from their Central Depository System (CDS) accounts maintained with Bursa Depository at anytime after the securities of the company have been de-listed from the Official List of Bursa Securities. This can be effected by the shareholders submitting an application form for withdrawal in accordance with the procedures prescribed by Bursa Depository. These shareholders can contact any Participating Organisation of Bursa Securities and/or Bursa Securities’ General Line at 03-2034 7000 for further information on the withdrawal procedures.

Upon the de-listing of the company, the company will continue to exist but as an unlisted entity. The company is still able to continue its operations and business and proceed with its corporate restructuring and its shareholders can still be rewarded by the company’s performance.  However, the shareholders will be holding shares which are no longer quoted and traded on Bursa Securities.

icy97

Type	Announcement
Subject	PRACTICE NOTE 17 / GUIDANCE NOTE 3 SUSPENSION AND/OR DELISTING
Description	BIOSIS GROUP BERHAD ("BIOSIS" OR THE "COMPANY")- APPEAL AGAINST THE REJECTION OF THE COMPANYS PROPOSED REGULARISATION PLAN- SUSPENSION AND/OR DELISTING OF BIOSIS
We refer to announcement on 18 November 2015 by Bursa Securities Malaysia Berhad (“Bursa Securities”) that Bursa Securities had dismissed the Company’s appeal against the rejection of the Company’s proposed regularisation plan and de-listing of the Company’s securities pursuant to Paragraph 8.04 of the Main Market Listing Requirements of Bursa Securities (“the Listing Requirements”). The Company wishes to inform that on 20 November 2015, the Company has filed an application at the High Court of Malaya at Kuala Lumpur, for an INJUNCTION to be granted to restrain Bursa Securities from delisting the Company’s securities from the Official List of Bursa Securities on Monday, 23 November 2015. This announcement is dated 21 November 2015.

icy97

Date of change	20 Nov 2015
Name	ENCIK JAMALUDIN BIN ELIS
Age	50
Nationality	Malaysia
Designation	Director
Directorate	Executive
Type of change	Resignation
Reason	Due to personal reasons.
Details of any disagreement that he/she has with the Board of Directors	No
Whether there are any matters that need to be brought to the attention of shareholders	No
Qualifications	1. Executive Certificate for MBA Holders, Harvard Business School (HBS), Harvard University (2008)2. MBA, Southern Cross University, Australia (2005)3. BSc. Engineering (Mechanical), Brighton Polytechnic (1988)
Working experience and occupation	1. Commercial Director of Pharmaniaga Berhad (2011-2014)2. Senior General Manager, Business Development/ Corporate Strategy of Pharmaniaga Berhad (2010-2011)        3. Senior General Manager Manufacturing Division of Pharmaniaga Manufacturing Berhad (2007-2009)4. General Manager (Plant) Safire Pharmaceuticals of Safire Pharmaceuticals Sdn Bhd (2005-2007)5. Factory Manager of Meditop Corporation Sdn Bhd (2002-2005)6. Business Development Manager of Inspired Technologies Sdn Bhd (1999-2001)7. Operations Director/Executive Director of Popular Profile Sdn Bhd (1994-1998)8. Manufacturing Engineer of Delta Switchgear Sdn Bhd (1988-1994)